Biontech SE
BNTX99.850USD
+1.000+1.01%
收盘 01/09, 16:00（美东）报价延迟15分钟
24.01B总市值
亏损市盈率 TTM
关于 Biontech SE 公司
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Biontech SE简介
公司代码BNTX
公司名称Biontech SE
上市日期Oct 10, 2019
CEOSahin (Ugur)
员工数量6772
证券类型Depository Receipt
年结日Oct 10
公司地址An der Goldgrube 12
城市MAINZ
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Germany
邮编55131
电话4949613190840
网址https://www.biontech.com/
公司代码BNTX
上市日期Oct 10, 2019
CEOSahin (Ugur)
Biontech SE公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+12755.00%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
+790.00%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
收入明细
单位: USD更新时间: 3月12日 周三
单位: USD更新时间: 3月12日 周三
FY2019
FY2018
FY2017
业务USD
名称
营收
占比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
由于公司未披露，未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
股东统计
更新时间: 11月15日 周六
更新时间: 11月15日 周六
持股股东
股东类型
持股股东
持股股东
占比
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
其他
38.36%
持股股东
持股股东
占比
AT Impf GmbH
39.32%
Medine GmbH
15.49%
Baillie Gifford & Co.
3.04%
Fidelity Management & Research Company LLC
1.92%
T. Rowe Price Investment Management, Inc.
1.87%
其他
38.36%
股东类型
持股股东
占比
Corporation
59.74%
Investment Advisor
15.63%
Investment Advisor/Hedge Fund
3.83%
Individual Investor
2.11%
Research Firm
1.19%
Hedge Fund
1.05%
Sovereign Wealth Fund
0.63%
Bank and Trust
0.22%
Pension Fund
0.18%
其他
15.43%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
774
54.93M
21.75%
-6.01M
2025Q3
808
54.84M
25.69%
-1.45M
2025Q2
821
56.21M
24.34%
+2.26M
2025Q1
832
54.17M
23.64%
-2.66M
2024Q4
855
52.85M
22.63%
+3.24M
2024Q3
827
49.68M
20.44%
+4.23M
2024Q2
801
45.24M
20.73%
+361.30K
2024Q1
817
44.34M
21.44%
-6.62M
2023Q4
879
44.00M
20.40%
+3.38M
2023Q3
904
40.73M
20.46%
-291.47K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
AT Impf GmbH
101.85M
40.33%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.13M
15.89%
-304.48K
-0.75%
Mar 31, 2025
Baillie Gifford & Co.
7.88M
3.12%
-159.51K
-1.98%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.98M
1.97%
-2.00M
-28.65%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
4.83M
1.91%
+1.24M
+34.32%
Sep 30, 2025
Flossbach von Storch AG
4.23M
1.68%
-65.00
-0.00%
Sep 30, 2025
PRIMECAP Management Company
3.87M
1.53%
-130.70K
-3.27%
Sep 30, 2025
Dodge & Cox
3.65M
1.44%
+2.77M
+315.65%
Sep 30, 2025
Sahin (Ugur MD)
2.05M
0.81%
-724.50K
-26.11%
Mar 31, 2025
Pfizer Inc
1.66M
0.66%
-2.00M
-54.67%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Langar Global HealthTech ETF
4.06%
iShares Genomics Immunology and Healthcare ETF
3.6%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Global X Genomics & Biotechnology ETF
3.11%
WisdomTree BioRevolution Fund
2.74%
Franklin Genomic Advancements ETF
2.46%
VanEck Biotech ETF
2.38%
Virtus LifeSci Biotech Products ETF
1.58%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.01%
查看更多
Langar Global HealthTech ETF
占比4.06%
iShares Genomics Immunology and Healthcare ETF
占比3.6%
First Trust NYSE Arca Biotechnology Index Fund
占比3.42%
Global X Genomics & Biotechnology ETF
占比3.11%
WisdomTree BioRevolution Fund
占比2.74%
Franklin Genomic Advancements ETF
占比2.46%
VanEck Biotech ETF
占比2.38%
Virtus LifeSci Biotech Products ETF
占比1.58%
ProShares Ultra Nasdaq Biotechnology
占比1.02%
Invesco Nasdaq Biotechnology ETF
占比1.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Biontech SE的前五大股东是谁？
Biontech SE 的前五大股东如下：
AT Impf GmbH持有股份：101.85M，占总股份比例：40.33%。
Medine GmbH持有股份：40.13M，占总股份比例：15.89%。
Baillie Gifford & Co.持有股份：7.88M，占总股份比例：3.12%。
Fidelity Management & Research Company LLC持有股份：4.98M，占总股份比例：1.97%。
T. Rowe Price Investment Management, Inc.持有股份：4.83M，占总股份比例：1.91%。
AT Impf GmbH持有股份：101.85M，占总股份比例：40.33%。
Medine GmbH持有股份：40.13M，占总股份比例：15.89%。
Baillie Gifford & Co.持有股份：7.88M，占总股份比例：3.12%。
Fidelity Management & Research Company LLC持有股份：4.98M，占总股份比例：1.97%。
T. Rowe Price Investment Management, Inc.持有股份：4.83M，占总股份比例：1.91%。
Biontech SE的前三大股东类型是什么？
Biontech SE 的前三大股东类型分别是：
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
AT Impf GmbH
Medine GmbH
Baillie Gifford & Co.
有多少机构持有Biontech SE(BNTX)的股份？
截至2025Q4，共有774家机构持有Biontech SE的股份，合计持有的股份价值约为54.93M，占公司总股份的21.75%。与2025Q3相比，机构持股有所增加，增幅为-3.93%。
哪个业务部门对Biontech SE的收入贡献最大？
在FY2019，Collaboration Revenue业务部门对Biontech SE的收入贡献最大，创收84.43M，占总收入的77.75%。
